Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 335

1.

[Is a presymptomatic malignant hyperthermia in-vitro diagnosis with 4-chloro-3-ethyl phenol possible? A study using porcine skeletal preparations].

Gerbershagen MU, Wappler F, Fiege M, Weisshorn R, Kolodzie K, Schulte am Esch J.

Anasthesiol Intensivmed Notfallmed Schmerzther. 2004 Feb;39(2):81-6. German.

PMID:
14767797
2.

[Theophylline induces contractures in porcine skeletal muscle preparations with the disposition to malignant hyperthermia].

Gerbershagen MU, Fiege M, Weisshorn R, Kolodzie K, Wappler F.

Anasthesiol Intensivmed Notfallmed Schmerzther. 2004 Mar;39(3):147-52. German.

PMID:
15042504
3.

Effects of the serotonin2 receptor agonist DOI on skeletal muscle specimens from malignant hyperthermia-susceptible patients.

Wappler F, Roewer N, Köchling A, Scholz J, Löscher W, Steinfath M.

Anesthesiology. 1996 Jun;84(6):1280-7.

PMID:
8669667
4.

Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.

Hartung E, Koob M, Anetseder M, Schoemig P, Krauspe R, Hogrefe G, Engelhardt W.

Acta Anaesthesiol Scand. 1996 Apr;40(4):437-44.

PMID:
8738688
5.

[4-chloro-m-cresol-induced contractures of skeletal muscle specimen from patients at risk for malignant hyperthermia].

Wappler F, Scholz J, von Richthofen V, Fiege M, Steinfath M, Schulte am Esch J.

Anasthesiol Intensivmed Notfallmed Schmerzther. 1997 Sep;32(9):541-8. German.

PMID:
9417254
6.

[Effects of serotonin 2 receptor agonists on skeletal muscle preparations in patients with a disposition toward malignant hyperthermia].

Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Rumberger E, Löscher W, Schulte am Esch J.

Anaesthesist. 1995 Aug;44(8):538-44. German.

PMID:
7573901
7.

[Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].

Fiege M, Wappler F, Scholz J, von Richthofen V, Brinken B, Schulte am Esch J.

Anasthesiol Intensivmed Notfallmed Schmerzther. 1998 Sep;33(9):557-63. German.

PMID:
9787864
8.

In vitro effects of 4-chloro-3-ethylphenol in skeletal muscle preparations from malignant hyperthermia susceptible and normal swine.

Gerbershagen MU, Wappler F, Fiege M, Weilsshorn R, Alberts PA, von Breunig F, Schulte am Esch J.

Eur J Anaesthesiol. 2002 Feb;19(2):135-40.

PMID:
11999597
9.

Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients.

Fiege M, Wappler F, Scholz J, Weisshorn R, von Richthofen V, Schulte am Esch J.

J Clin Anesth. 2000 Mar;12(2):123-8.

PMID:
10818326
10.

Ritanserin attenuates the in vitro effects of the 5-HT2 receptor agonist DOI on skeletal muscles from malignant hyperthermia-susceptible patients.

Wappler F, Scholz J, Oppermann S, von Richthofen V, Steinfath M, Schulte am Esch J.

J Clin Anesth. 1997 Jun;9(4):306-11.

PMID:
9195354
11.

5-HT2 receptor antagonist-mediated inhibition of halothane-induced contractures in skeletal muscle specimens from malignant hyperthermia susceptible patients.

Wappler F, Scholz J, Fiege M, Richter A, Steinfath M, Weisshorn R, Schulte am Esch J.

Naunyn Schmiedebergs Arch Pharmacol. 1999 Oct;360(4):376-81.

PMID:
10551274
12.

Phosphodiesterase-III-inhibition with amrinone leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swine.

Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Kolodzie K, Schulte am Esch J.

Eur J Anaesthesiol. 2005 Apr;22(4):283-8.

PMID:
15892406
13.

Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.

Weisshorn R, Wappler F, Fiege M, Gerbershagen MU, Kolodzie K, Alberts P, Horn EP, Schulte Am Esch J.

J Clin Anesth. 2004 Aug;16(5):353-7.

PMID:
15374556
14.

Attenuation of serotonin-induced contractures in skeletal muscle from malignant hyperthermia-susceptible patients with dantrolene.

Wappler F, Scholz J, von Richthofen V, Fiege M, Köchling A, Lambrecht W, Schulte am Esch J.

Acta Anaesthesiol Scand. 1997 Nov;41(10):1312-8.

PMID:
9422298
15.

Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.

Gilly H, Musat I, Fricker R, Bittner RE, Steinbereithner K, Kress HG.

Anesth Analg. 1997 Jul;85(1):149-54.

PMID:
9212139
16.

In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine.

Fiege M, Wappler F, Weisshorn R, Gerbershagen MU, Kolodzie K, Schulte Am Esch J.

Anesthesiology. 2003 Apr;98(4):944-9.

PMID:
12657857
17.

Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility.

Wappler F, Anetseder M, Baur CP, Censier K, Doetsch S, Felleiter P, Fiege M, Fricker R, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Hopkins PM, Klingler W, Lehmann-Horn F, Nivoche Y, Tegazzin V, Tzanova I, Urwyler A, Weisshorn R, Schulte am Esch J.

Eur J Anaesthesiol. 2003 Jul;20(7):528-36.

PMID:
12884985
18.

In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.

Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F.

Acta Anaesthesiol Scand. 1997 Sep;41(8):955-66.

PMID:
9311391
19.
20.

In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles.

Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Schulte am Esch J.

Anesth Analg. 1996 Jun;82(6):1230-6.

PMID:
8638796
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk